• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

EAN HIGHLIGHTS – TUESDAY, JUNE 24, 2025

June 24, 2025  

EAN HIGHLIGHTS – MONDAY, JUNE 23, 2025

June 23, 2025  

DMT prescribing in Canada – Part 2

June 12, 2025  

DMT prescribing in Canada – survey results

June 6, 2025  

Treatment discontinuation in MS: the DOT-MS trial

May 5, 2025  

CLINICAL CASES IN MS: A 24 Y.O. WOMAN WITH PARESTHESIAE AND NON-ENHANCING LESIONS

April 25, 2025  

AAN 2025 – report on fluid biomarkers in MS

April 22, 2025  

Ofatumumab – new data on efficacy and safety

April 14, 2025  

AAN DAILY HIGHLIGHTS – WEDNESDAY, APRIL 9, 2025

April 9, 2025  

AAN DAILY HIGHLIGHTS – TUESDAY, APRIL 8, 2025

April 8, 2025  
Previous
1
2
3
4
Next

Browse by Topic

  • EPILEPSY (37)
  • ECTRIMS 2025 (7)
  • MS (426)
  • BIOMARKERS IN MS (60)
  • Library (18)
  • CLINICAL CASES IN MS (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • ECTRIMS 2025 HIGHLIGHTS – FRIDAY, SEPTEMBER 26, 2025 posted on September 26, 2025
  • Early use and long-term safety of ofatumumab: highlights from ECTRIMS 2025 posted on October 7, 2025
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions